Capecitabine + irinotecan cost effective for colorectal cancer in China

  • PDF / 167,168 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 88 Downloads / 206 Views

DOWNLOAD

REPORT

1173-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864

1

Data Loading...

Recommend Documents
Capecitabine/irinotecan/oxaliplatin

154 79 166KB

Bevacizumab + capecitabine not cost effective in mCRC

162 48 111KB

Which oesophageal cancer screening strategy is cost effective in China?

144 60 163KB

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

155 72 993KB

Trastuzumab cost effective in early breast cancer

115 43 122KB

Preoperative lymphoscintigraphy cost effective in vulvar cancer

157 31 166KB

Cost-Effectiveness Analysis of Colorectal Cancer Screening

180 5 5MB

Tucatinib not cost effective in metastatic breast cancer in China and US

104 8 163KB

Is population genomic screening for breast/ovarian cancer cost effective?

101 72 163KB

Lenvatinib cost effective in advanced liver cancer in Australia

172 41 163KB

Olaparib cost effective for advanced BRCA -associated ovarian cancer

145 30 168KB

Pegfilgrastim more cost effective than filgrastim in breast cancer

105 70 124KB